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Abstract
Background: A pilot study was performed in order to investigate the effects of bariatric surgery on whole blood gene
expression profiles in obese subjects with type 2 diabetes.
Methodology/Principal Findings: Whole blood from eleven obese subjects with type 2 diabetes was collected in PAXgene
tubes prior to and 6–12 months after bariatric surgery. Total RNA was isolated, amplified, labeled and hybridized to Illumina
gene expression microarrays. Clinical and expression data were analyzed using a paired t-test, and correlations between
changes in clinical trait and transcript levels were calculated. Pathways were identified using Ingenuity Pathway Analysis
and DAVID gene ontology software. Overall, bariatric surgery resulted in significant reduction of body mass index, fasting
plasma glucose, fasting plasma insulin, and normalization of glycosylated hemoglobin levels. The expression levels of 204
transcripts, representing 200 unique genes, were significantly altered after bariatric surgery. Among the significantly
regulated genes were GGT1, CAMP, DEFA1, LCN2, TP53, PDSS1, OLR1, CNTNAP5, DHCR24, HHAT and SARDH, which have been
previously implicated in lipid metabolism, obesity and/or type 2 diabetes. Selected findings were replicated by quantitative
real-time-PCR. The changes in expression of seven transcripts, WDR35, FLF45244, DHCR24, TIGD7, TOPBP1, TSHZ1, and
FAM8A1 were strongly correlated with the changes in body weight, fasting plasma glucose and glycosylated hemoglobin
content. The top pathways associated with gene expression changes after bariatric surgery was lipid metabolism, small
molecule biochemistry and gene expression. Two antimicrobial peptides were among the transcripts with the largest
changes in gene expression after bariatric surgery.
Conclusions/Significance: Data from this pilot study suggest that whole blood expression levels of specific transcripts may
be useful as biomarkers associated with susceptibility for type 2 diabetes and/or therapeutic response.
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Introduction
The prevalence of obesity and type 2 diabetes has increased
dramatically in the past decades accompanied by an array of
secondary health issues [1]. Both obesity and diabetes are features
of the metabolic syndrome, which increases ones risk for
cardiovascular diseases. Obesity is a key factor contributing to
the development of type 2 diabetes; and, weight loss is associated
with improvements in glucose homeostasis. Bariatric surgery
represents one of the most efficacious methods for the treatment
of obesity and type 2 diabetes; and, it often leads to normalization
of hyperglycemia and insulin resistance prior to significant weight
loss [2,3]. Furthermore, bariatric surgery results in sustained
weight loss and resolution of type 2 diabetes in a majority of
patients with a higher success rate compared to that obtained
through diet/lifestyle changes and pharmacotherapy [4].
The main objective of the present pilot study was to examine
changes in whole blood gene expression in obese subjects with type
2 diabetes before and after bariatric surgery, which resulted in
weight loss and improved hyperglycemia for all subjects. We chose
to observe gene expression changes in whole blood, as this tissue
may reflect a systemic response to altered metabolism, and it is the
easiest tissue to obtain for serial sampling in a clinical setting. In 11
subjects studied before and after surgery, we found 200 unique
genes whose expression was significantly altered, many of which
have been previously implicated in obesity and/or type 2 diabetes.
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Study design
The complete clinical characteristics of subjects that participat-
ed in this study are given in Table S1. The study was conducted in
accordance with the appropriate clinical and experimental ethical
guidelines and was approved by the Cleveland Clinic Institutional
Review Board. Written informed consent was obtained by the
subjects before their participation. Eleven obese subjects with type
2 diabetes, (5 females and 6 males), with an average age at
enrollment 50.5611.9 (mean 6 SD) were studied. Roux-en-Y
gastric bypass surgery (RYGB) was performed on seven subjects, (3
females and 4 males), while 4 subjects underwent Sleeve
Gastrectomy (SG). None of the women were taking hormonal
therapy, no subjects used steroid medications, and none were
smokers. Of the 11 subjects, 9 were taking metformin, 2 were
taking pioglitazone, and 4 were taking sulfonylureas as oral
diabetes medications prior to surgery. Diabetes medications were
discontinued by 6 weeks after surgery. Following a 10–12 hour
overnight fast, peripheral blood was drawn for clinical laboratory
tests and transcriptome analysis 2 weeks prior to and 6–12 months
after intervention. All medications were withheld at least 24 hours
prior to blood draw on both occasions.
Isolation of total RNA
Whole blood samples (2.5 ml) from each subject were collected
in PAXgene Blood RNA tubes (BD, Franklin Lakes, NJ) which
lyses the cells and stabilizes the RNA. Samples were incubated for
two hours at room temperature to ensure the complete lysis of
blood cells. Total RNA was isolated using PAXgene Blood RNA
Kit (Qiagen, Valencia, CA) following manufacturer’s guidelines
and stored at 280uC. RNA quality was evaluated by incubating
200 ng RNA at 37uC overnight and analyzed by gel electropho-
resis.
Hybridization and microarray data analysis
An aliquot of total RNA for each sample was amplified and
biotin labeled using Ovation RNA amplification System V2
(NuGEN, San Carlos, CA). Purified biotin-labeled cDNA was
hybridized to HumanWG–6 v2 Expression BeadChip microarrays
(Illumina, San Diego, CA) according to the manufacturer’s
instructions. The hybridization temperature was reduced to
48uC to adjust the conditions for hybridization of cDNA rather
than cRNA. The arrays were scanned on the Illumina BeadArray
Reader using Illumina BeadScan software. Data were quantile
normalized without background subtraction using Illumina
BeadStudio software. To reduce the chip-to-chip variability the
control (pre-surgery) and post-surgery samples for each patient
were put on the same microarray chip. A two-tailed paired t-test
analysis was performed to identify the genes whose expression
levels changed significantly after the surgery. Only the genes with
an unadjusted paired t-test p-value,0.01 were further analyzed
and reported. To correct for multiple testing the False Discovery
Rate (FDR) Q-value estimates were calculated using QVALUE
software (http://www.genomics.princeton.edu/storeylab/qvalue/
index.html) [5,6]. Fold changes in gene expression were calculated
as the average of value post/value pre from each of the 11
subjects, and converted to % changes (i.e. 1.40 fold=40% increase
and 0.60 fold=40% decrease). In order to correlate changes in
expression level of each transcript with changes in the clinical
values, we calculated, expression levels and clinical values as (value
post – value pre)/value pre, and the mean for all subjects was
expressed as percent change. Gene ontology, biological networks,
and canonical pathways were evaluated with Ingenuity Pathway
Analysis software (www.ingenuity.com) and the DAVID Annota-
tion Tool website (http://david.abcc.ncifcrf.gov) [7,8]. The
microarray dataset from this study is available through the Gene
Expression Omnibus server, accession number GSE19790. All
microarray data are MIAME compliant. Correlation analysis were
performed to identify the significantly regulated genes whose
changes in expression levels were best associated with changes in
weight loss, BMI, fasting plasma glucose, and WBC count.
Real-time quantitative PCR (qPCR)
To validate the microarray findings, the expression levels of
cathelicidin antimicrobial peptide (CAMP), alpha defensin 1
(DEFA1), and carcinoembrionic antigen-related cell adhesion
molecule 8 (CEACAM8) were quantified relative to the endogenous
control gene, beta actin (ACTB) using pre-designed TaqMan gene
expression assays (Applied Biosystems, Foster City, CA). Mean
fold changes for each sample were calculated by using the 2
2DDCt
method as previously described [9].
Protein expression and clinical assays
Human plasma levels of lipocalin 2 (also known as NGAL) were
determined using a rapid ELISA kit (BioPorto Diagnostics,
Gentofte, Denmark) following the manufacturer’s protocol. Serum
gamma-glutamyltransferase 1 activity and all other clinical values
were determined by standard clinical assays performed by the
Cleveland Clinic Pathology and Laboratory Medicine Institute.
Gamma-glutamyltransferase activity must be measured in serum,
which was only available for six pairs of samples.
Results
Clinical and metabolic effects of bariatric surgery
The diabetes related clinical characteristics of the subjects
before and after surgery are presented in Table 1 and the complete
clinical data for each subject are presented in Table S1. Overall,
bariatric surgery had a positive impact on weight loss and
resolution of hyperglycemia for every subject included in this
study, leading to significant decreases of 22% in mean weight
(p=9.1610
27), 21.0% in mean BMI (p=9.9610
27), 42% in
fasting plasma glucose (p=8.6610
24), 26% in mean glycosylated
hemoglobin (HbA1C) content (p=5.9610
24), and 80% in fasting
plasma insulin (p=0.042). Other significant changes include a
12% decrease in white blood cell count (p=0.016), a 31%
decrease in mean VLDL-cholesterol (p=0.036), a 54% decrease
in plasma alanine aminotransferase activity (p=7.5610
24), a 7%
decrease in % neutrophils (p=0.01), and a 14% increase in
percent lymphocytes (p=0.007). Although this pilot study was not
designed or powered to compare the two types of surgery, we
observed that the seven subjects who underwent RYGB surgery
were more responsive in weight loss and resolution of type 2
diabetes than the four SG surgery subjects, with larger percent
decreases in BMI (24% and 18% decreases for RYGB and SG,
respectively, p=0.016), fasting plasma glucose (45% and 28%,
respectively, p=0.086), and HbA1C (30% and16%, respectively,
p=0.064). Post surgery, all seven of the RYGB subjects and only
one of four SG subjects met the criterion for normal fasting plasma
glucose of ,100 mg/dL (p=0.007 by chi square test).
Gene expression profiling
Of the 48,804 probes on the microarray, 17,115 probe IDs were
called present (Illumina detection p-value#0.05) in 10 or more of
the 22 total samples, which were used in subsequent analyses (10
was chosen to reduce the noise while maintaining any potential
gender specific expressed transcripts in the five paired female and
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we were not powered to compare the effects of the two types of
surgery on gene expression, thus all subjects were pooled for our
analyses. 204 (,1.7%) of the transcripts were identified as
differentially expressed due to the bariatric surgery at a p-
value,0.01 (Table S2). Because some transcripts had more than
one probe on the array, these 204 transcripts represent 200 unique
genes. To correct for multiple testing, we estimated the false
discovery rate (FDR) at p,0.01 to be 0.52, thus, at the considered
cutoff we would expect 107 transcripts to appear differentially
expressed solely by chance (compared to the 204 differentially
expressed transcripts observed). Of the 204 differentially expressed
transcripts, 115 (56%) were down regulated and 89 (44%) were up
regulated. The top 25 significantly differentially expressed
transcripts ranked by p-value are displayed in Table 2. None of
the 204 transcripts had a 2- or greater fold change, and only 17
(8.3%) were altered by more than 25%, with 8 being down
regulated and 9 up regulated (Table 3).
The transcript with the most significant p-value overall encodes
for gamma-glutamyltransferase 1 (GGT1); and, although its
expression was only reduced by 10% post-surgery, this change
was consistent in all subjects. The transcript with the third most
significant p-value overall encodes for cathelicidin antimicrobial
peptide (CAMP), which was reduced by 41% post surgery. The
microarray contained three probes that align to both alpha
defensin 1 (DEFA1) and alpha defensin 3 (DEFA3), which ranked
first, third and fourth of those genes with the largest percent
change in gene expression (45 to 46% down regulated, Table 3),
demonstrating internal consistency in this finding. Thus, two
separate antimicrobial peptides (CAMP and DEFA1/A3) were
relatively highly down regulated. Other transcripts that were
relatively highly down regulated include lipocalin 2 (LCN2) and
carcinoembryonic antigen-related cell adhesion molecule 8
(CEACAM8), with 46% and 45% reductions post-surgery,
respectively (Table 3).
Quantitative real-time PCR (qPCR)
To confirm the microarray data we performed qPCR for three
relatively highly regulated and robustly expressed transcripts:
DEFA1, CAMP, and CEACAM8 (Table 4). Paired t-test p-values for
the effect of bariatric surgery on transcript expression levels were
found to be consistent with the microarray data; and, the percent
changes after surgery were similar or greater than the percent
changes detected by microarray (Table 4). The expression levels of
these three transcripts were compared between the microarray
and qPCR data for the 22 (pre and post-surgery) samples using
linear regression analysis; and, each transcript had a very strong
positive correlation (R values ranged from 0.75 to 0.88).
Plasma protein assays
To determine whether the protein levels follow the same
expression pattern as their transcripts we measured the activity or
level of two serum proteins, gamma-glutamyltransferase and
lipocalin 2. Serum gamma-glutamyltransferase activity was
reduced in the post-surgery samples by an average of 38%
(p=0.05, paired t-test), consistent with the direction of change
observed for GGT1 mRNA levels in whole blood. Plasma levels of
lipocalin 2 were determined in 8 subjects pre and post surgery, and
its levels were significantly increased after the surgery by an
average of 34% (p=0.008), which is opposite to the whole blood
LCN2 mRNA levels that were significantly decreased. This
discrepancy may be due to the majority of plasma lipocalin 2
being synthesized in tissues other than blood such as adipocytes
and liver [10,11].
Pathway and correlation analyses
To identify the biological mechanisms, pathways and functions
most relevant to the genes of interest, the differentially expressed
transcripts (p,0.01) were subjected to Ingenuity Pathway
Analysis. The top scoring network identified was ‘‘lipid metabo-
lism, small molecule biochemistry and free radical scavenging’’
(Figure 1). Of the 23 genes involved in the network, 16 were down
regulated and seven were up regulated. Also, the differentially
expressed transcripts were subjected to canonical pathways
analysis via Ingenuity Pathways Analysis software. The following
pathways (together with their respective genes) were the most
significantly represented canonical pathways (Fisher’s exact test p-
value,0.05): myc-mediated apoptosis signaling (FASq, SHC1Q
and TP53Q); thyroid cancer signaling (SHC1Q and TP53Q);
fatty acid metabolism (ADHFE1q, CPT1AQ, CYP51A1Q and
SLC27A6Q); iCOS-iCOSL signaling in T-helper cells (PLE-
KHA3q, PPP3CCq and SHC1Q); and glycine, serine and
threonine metabolism (GNMTQ, SARDHQ and SMOXQ).
Linear regression analysis was performed in order to identify
changes in transcript expression that were best correlated with
changes in weight, FPG, HbA1C, and WBC count, using an
arbitrary R
2 cutoff of $0.25. We found that expression changes in
20 regulated transcripts (9.8% of the 204 identified) were highly
correlated with changes in weight (Table S3). Of these 20
transcripts, 12 were found to be inversely correlated and 8 were
Table 1. Diabetes related clinical characteristics of subjects involved in the study.
Clinical Characteristic Pre-surgery
a Post-surgery
a % Change P- value
b
% Change
RYGB %Change SG P-value
c
Weight (kg) 140.7635.1 110.4629.9 221.5 9.08E-07 224 218 0.033
BMI (kg/m
2)4 7 . 1 611.6 37.2610.0 221.0 9.90E-07 224 217 0.016
Fasting plasma glucose (mg/dL) 170654.2 97.8626.5 242.5 8.57E-04 245 228 0.086
Fasting plasma insulin (mIU/ml)
d 32.2635.4 6.664.8 279.5 4.25E-02 279 253 0.135
HbA1c (%) 7.961.5 5.960.6 226.3 5.87E-04 230 216 0.064
a, Data are means 6 SD for 11 subjects pre- and post surgery.
b, Unadjusted paired T-test comparing pre- vs. post surgery.
c, T-test comparing % change by RYBG vs. SG.
d, Data only available for 9 subjects before and after surgery.
BMI, Body mass index.
HbA1C, glycosylated hemoglobin A1C.
doi:10.1371/journal.pone.0016729.t001
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RANK PROBE_ID GENE Symbol Paired T-Test % Change DEFINITION
1 ILMN_1652604 GGT1 6.35E-05 210% Gamma-glutamyltransferase 1, transcript variant 4.
2 ILMN_1736238 GNMT 9.49E-05 27% Glycine N-methyltransferase.
3 ILMN_1688580 CAMP 1.76E-04 241% Cathelicidin antimicrobial peptide.
4 ILMN_1682312 CYBB 2.24E-04 213% Cytochrome b-245, beta polypeptide (chronic granulomatous disease).
5 ILMN_1768399 ARFIP1 3.64E-04 29% ADP-ribosylation factor interacting protein 1, transcript variant 1.
6 ILMN_1781028 ZMYM5 4.18E-04 20% Zinc finger, MYM-type 5, transcript variant 1.
7 ILMN_1727740 SYNCRIP 4.59E-04 20% Synaptotagmin binding, cytoplasmic RNA interacting protein.
8 ILMN_1797682 INSL3 4.81E-04 213% Insulin-like 3 (Leydig cell).
9 ILMN_1714987 TRIM54 5.04E-04 218% Tripartite motif-containing 54, transcript variant 1.
10 ILMN_1675413 ENPP7 5.06E-04 211% Ectonucleotide pyrophosphatase/phosphodiesterase 7.
11 ILMN_1813091 ARL1 5.84E-04 9% ADP-ribosylation factor-like 1.
12 ILMN_1748384 BOC 6.02E-04 15% Boc homolog (mouse).
13 ILMN_1759017 ZNF333 6.44E-04 15% Zinc finger protein 333.
14 ILMN_1912287 HS.133181 7.69E-04 211% BX093329 Soares_parathyroid_tumor_NbHPA cDNA clone.
15 ILMN_1775570 FLJ44635 8.33E-04 29% TPT1-like protein.
16 ILMN_1656371 TRPA1 9.35E-04 210% Transient receptor potential cation channel, subfamily A, member 1.
17 ILMN_1689294 LOC85390 9.46E-04 16% RNA, small nucleolar on chromosome 11.
18 ILMN_1911981 HS.197709 9.90E-04 22% AGENCOURT_8291102 Lupski_sympathetic_trunk cDNA clone
19 ILMN_1679357 DEFA1/DEFA3 1.08E-03 246% Defensin, alpha 1/Defensin alpha 3.
20 ILMN_1804631 CNBP 1.11E-03 13% CCHC-type zinc finger, nucleic acid binding protein.
21 ILMN_1725661 DEFA1/DEFA3 1.16E-03 245% Defensin, alpha 1/Defensin alpha 3.
22 ILMN_1815777 NBPF12 1.16E-03 211% PREDICTED: neuroblastoma breakpoint family, member 12.
23 ILMN_1687567 CUTL1 1.25E-03 210% Cut-like 1, CCAAT displacement protein, transcript variant 1.
24 ILMN_1672246 OR4C15 1.30E-03 211% Olfactory receptor, family 4, subfamily C, member 15.
25 ILMN_1893704 HS.541159 1.31E-03 14% 7n45b12.x1 NCI_CGAP_Lu24 cDNA clone IMAGE:3567335 3.
doi:10.1371/journal.pone.0016729.t002
Table 3. Differentially expressed transcripts with .25% change in expression following bariatric surgery.
PROBE_ID GENE Symbol P-value
a % Change DEFINITION
ILMN_1679357 DEFA1/DEFA3 1.08E-03 246% Defensin, alpha 1/definsin alpha 3.
ILMN_1692223 LCN2 4.37E-03 246% Lipocalin 2 (oncogene 24p3).
ILMN_1725661 DEFA1/DEFA3 1.16E-03 245% Defensin, alpha 1/defensin alpha 3
ILMN_1693262 DEFA1/DEFA3 1.65E-03 245% Defensin, alpha 1/defensin alpha 3
ILMN_1806056 CEACAM8 3.73E-03 245% Carcinoembryonic antigen-related cell adhesion molecule 8.
ILMN_1688580 CAMP 1.76E-04 241% Cathelicidin antimicrobial peptide.
ILMN_1723035 OLR1 8.09E-03 237% Oxidized low density lipoprotein (lectin-like) receptor 1.
ILMN_1762713 C19ORF59 6.53E-03 229% Chromosome 19 open reading frame 59.
ILMN_1690546 PPP3CC 6.21E-03 26% Protein phosphatase 3 catalytic subunit, gamma isoform.
ILMN_1805271 ZNF721 6.81E-03 26% Zinc finger protein 721.
ILMN_1813400 CBR4 8.96E-03 26% Carbonyl reductase 4.
ILMN_1702858 ADHFE1 3.78E-03 27% Alcohol dehydrogenase, iron containing, 1.
ILMN_1748476 NOP5/NOP58 2.49E-03 28% Nucleolar protein NOP5/NOP58.
ILMN_1661940 CAMTA1 4.40E-03 28% Calmodulin binding transcription activator 1.
ILMN_1656111 MYLIP 3.83E-03 29% Myosin regulatory light chain interacting protein.
ILMN_1797893 PFAAP5 5.93E-03 31% Phosphonoformate immuno-associated protein 5.
ILMN_1679045 SBDS 6.03E-03 39% Shwachman-Bodian-Diamond syndrome.
a, Paired T-test pre- and post-surgery.
doi:10.1371/journal.pone.0016729.t003
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inversely correlated with changes in weight encodes for prenyl
(decaprenyl) diphosphate synthase subunit 1 (PDSS1,R=20.80).
Gene ontology (GO) analysis of the 20 transcripts best correlated
with weight change revealed two related GO terms that were
significantly represented, cholesterol biosynthetic process
(p=1.23E-04) and sterol biosynthetic process (p=2.21E-04, Table
S4).
Changes in 35 regulated transcripts (17.2% of the 204
identified) were highly correlated with changes in FPG. More
transcripts were inversely correlated than positively correlated (23
versus 12). The transcript best correlated with changes in FPG was
HHAT (R=20.79), which encodes the hedgehog acyltransferase
enzyme. Changes in 32 regulated transcripts (15.7% of the 204
identified) were strongly correlated with changes in HbA1C levels,
of which 23 were inversely and 9 transcripts were positively
correlated (Table S3) The distributions for positive and/or inverse
correlations were not significantly different for this or any of the
other correlations via chi-square tests. The transcript best and
inversely correlated with changes in HbA1C content (R=20.75)
encodes for the WD repeat 35 protein (WDR35). We looked for
transcripts that were correlated to more than one of these clinical
traits, and we found many that were highly correlated with two or
more traits, and seven that were highly correlated with all three
traits (Figure 2). These seven transcripts were WDR35, FLJ45244,
DHCR24, TIGD7, TOPBP1, TSHZ1 and FAM8A1 (Table S3).
Changes in the expression of 27 transcripts (13.24% of the 204
identified) were strongly correlated with changes in WBC count,
with 16 inversely and 11 positively correlated. Two of our top
three differentially expressed transcripts, GGT1 and CAMP, were
highly and positively correlated with changes in WBC count
(R=0.63 and 0.56, respectively, Table S3).
Discussion
This pilot study was designed to examine the clinical and
biochemical changes induced by bariatric surgery and their
association with changes in whole blood gene expression in obese
subjects with type 2 diabetes. This is the first study that we are
aware of comparing the whole blood transcriptome in subjects
before and after bariatric surgery. Our pilot study identified ,200
transcripts whose expression levels in whole blood were signifi-
cantly changed after bariatric surgery, some of which were
previously reported to be implicated in obesity and/or type 2
diabetes. Although we observed consistent reductions in body
weight, BMI, fasting plasma glucose, and HbA1C levels following
bariatric surgery, we did not specifically measure changes in body
fat composition. Thus, we were not able to determine the degree of
correlation between changes in gene expression and changes in
body fat composition among the 11 subjects. Overall, we observed
more changes in gene expression correlated with changes in the
measures of diabetes related traits (fasting plasma glucose and
HbA1C levels) than we observed with changes in body weight, thus
implying that the resolution of diabetes had a stronger influence on
whole blood gene expression than the loss of body weight.
We searched the literature and the Gene Expression Omnibus
database (http://www.ncbi.nlm.nih.gov/geo) for prior transcrip-
tome profiling studies in humans following bariatric surgery or
weight loss. One study examined the skeletal muscle transcriptome
in three human subjects before and after bariatric surgery. Twenty
genes were differentially expressed using a paired t-test, and all of
them were reduced 12 months after surgery with decreases
ranging from 25 to 66% [12]. In another study, Ghosh et al.,
compared whole blood gene expression profiles in lean and obese
subjects [13]; although, the Ghosh study used the same source of
RNA as the current study, it did not compare subjects prior to and
after weight loss using a paired t-test analysis. However, Ghosh
deposited additional whole blood gene expression profiles from 10
obese subjects before and after a 6-week diet period which led to
weight loss (GEO accession # GSE18897). We analyzed this
dataset using the same paired t-test as algorithm as in the current
study, and found 388 probes that were significantly different using
the unadjusted p-value threshold of ,0.01. The expression levels
of 194 genes were reduced after weight loss with decreases ranging
from 7 to 63%.
In the present study, we found that bariatric surgery led to
significantly decreased levels of serum alanine aminotransferase
(ALT) (54% decrease), plasma VLDL-cholesterol, and serum
gamma-glutamyltransferase (GGT) activity. Given previously
reported association of elevated serum VLDL, ALT and GGT
levels with hepatic steatosis in obese and type 2 diabetes subjects,
and the positive effects of bariatric surgery to reverse hepatic
steatosis and the levels of these markers [14], their decreased levels
in our study likely reflect the reduction of hepatic fat and
improvement in liver function following bariatric surgery. Other
studies report that serum levels of GGT are positively and strongly
associated with the increased risk of type 2 diabetes over a period
of three years [15,16], and associated with increased risk for fatal
cardiovascular disease (CVD) [17]. We found a decrease in whole
blood GGT1 mRNA levels, the transcript with the most significant
p-value in our study. Since the liver is thought to be the major
source of serum GGT activity [18], we speculate that the liver and
blood levels of GGT1 mRNA may be coordinately regulated. The
human GGT1 gene has multiple promoters and is alternatively
spliced leading to several mRNA isoforms [19]. Several studies
have reported a complex regulation of GGT1 transcription upon
exposure to oxidative stress [20]; however, it not known whether
liver and blood express the same isoforms of GGT1 mRNA and the
pathways that regulate GGT1 expression in these tissues are not
well defined. In conclusion, our observed decrease in whole blood
GGT1 mRNA levels along with decreased FPG levels after
bariatric surgery in the current study are consistent with these















DEFA1 0.88 2.99E-03 1.08E-03 264% 246%
CAMP 0.75 1.01E-03 1.76E-04 243% 241%
CEACAM8 0.86 1.08E-02 3.73E-03 257% 245%
a, P-values of linear regression analysis are all significant (p,0.05).
b, Two-tailed paired t-test based on comparing transcript levels pre- vs. post- surgery.
doi:10.1371/journal.pone.0016729.t004
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in those at most risk for type 2 diabetes.
A variety of acute-phase proteins are increased in subjects with
obesity and type 2 diabetes [21]; while, several acute phase
reactant proteins have been shown to decline following bariatric
surgery [22]. We found that the mRNA levels of two
antimicrobial peptides, cathelicidin antimicrobial peptide (CAMP)
and alpha defensin 1/3 (DEFA1/DEFA3), were significantly
decreased after bariatric surgery. In two prior studies, plasma
levels of alpha defensins were found to be decreased by 55 to 60%
in women after bariatric surgery, and their levels were correlated
with changes in plasma triglyceride levels and pathology based
measures of liver steatosis and inflammation [23,24]. Thus, our
finding of decreased DEFA1/DEFA3 mRNA levels after bariatric
surgery agrees with prior findings from plasma protein level
measurement assays.
Figure 1. Lipid metabolism, small molecule biochemistry, free radical scavenging network. The straight lines represent direct
relationships and the dotted lines represent indirect relationships. Up regulated and down regulated genes that meet the P-value cutoff of ,0.01 are
shown in red and green shading respectively, with color intensity related to the fold change in expression. The molecules that do not meet the
abovementioned P-value cutoff are shown in gray, while the molecules that are incorporated in the network through relationships with other
molecules and are not user specified are shown in white. Symbols used in the figure represent: trapezoid, transporter; circle, other; concentric circles,
complex/group; dotted square, growth factor; vertical rhombus, enzyme; horizontal rhombus, peptidase; vertical oval, transmembrane receptor;
horizontal oval, transcription regulation.
doi:10.1371/journal.pone.0016729.g001
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significantly (46%) reduced after surgery. LCN2 has been
classified as an adipokine that increases expression of PPARc
and adiponectin in 3T3-L1 adipocytes, and suppresses LPS-
induced macrophage cytokine production [25]. Lcn2 mRNA is
increased in the liver and adipose tissue of obese Lepr
db/db vs. wild
type mice [26]. Also, lipocalin 2 protein levels are higher in obese
vs. lean humans [26]. Furthermore, plasma lipocalin 2 levels are
positively correlated with BMI, adiposity, hyperglycemia, and
insulin resistance [26]. Lipocalin 2 has also been implicated in
innate immunity, as Lcn2-deficient mice are more susceptible to
bacterial infection [26]. Although blood LCN2 mRNA was
decreased after surgery in our study, we found that plasma
lipocalin 2 levels increased after surgery, which may be attributed
to increased secretion from another tissue source. Although our
observed effects of surgery on plasma lipocalin 2 levels are not
concordant with the prior correlations, we are not aware of any
other studies measuring plasma lipocalin 2 before and after
bariatric surgery.
Tumor protein p53 (TP53) is another transcript that we
identified that was down regulated after bariatric surgery. A
recent study has reported that adipose tissue p53 plays a crucial
role in the regulation of insulin resistance [27]. Increased
expression of p53 was found to be associated with an increased
production of proinflammatory cytokines that led to insulin
resistance, while decreased expression had the opposite effect on
proinflamatory cytokines and was associated with improved insulin
resistance in mice with type 2 diabetes-like disease [27]. Thus, our
finding of decreased whole blood TP53 mRNA after bariatric
surgery, weight loss, and remission of type 2 diabetes is consistent
with this prior study.
The lectin-like low density lipoprotein receptor 1 (OLR1) gene,
also known as LOX1, encodes for a protein that can be
proteolytically cleaved and released as soluble form in serum.
Whole blood OLR1 mRNA levels were significantly decreased by
37% after bariatric surgery in our study, consistent with a previous
study reporting that the serum levels of the sLOX1 protein is
higher in type 2 diabetes patients than in controls [28].
Human genome wide association studies have identified many
SNPs associated with type 2 diabetes. Four genes with common
SNPs that were previously identified to be associated with type 2
diabetes [29–31] are found in our list of 204 transcripts whose
expression was altered after bariatric surgery. Surgery induced
changes in expression of all four of these genes were found to be
highly correlated with surgery induced changes in HbA1C content.
These four genes are: contactin associated protein-like 5
(CNTNAP5, decreased after surgery), 24-dehydrocholesterol re-
ductase (DHCR24, decreased), hedgehog acyltransferase (HHAT,
increased), and sarcosine dehydrogenase (SARDH, decreased). The
finding that two distinct methods, genetic association with type 2
diabetes and transcriptome profiling after bariatric surgery, yield
four identical gene hits highlights a potential for gene environ-
mental interactions playing an important role for these specific
genes and their influence on glucose homeostasis.
DHCR24 was also one of seven genes whose change in
expression level after bariatric surgery was positively and highly
correlated with changes in the three examined clinical phenotypes:
HbA1C content, weight, and FPG. DHCR24 encodes an enzyme
participating in sterol biosynthesis; however, it also binds to p53
and protects it from degradation leading to cellular defense against
oxidative stress [32,33]. DHCR24 is up regulated in endothelial
cells by exposure to HDL, and the HDL mediated lowering of NF-
kB and VCAM expression is dependent upon DHCR24 expression
[34]. The decrease in expression of both DHCR24 and TP53 in
whole blood after surgery reinforces the concept that surgically
induced weight loss and remission of type 2 diabetes may alter
WBC p53 pathways; however, the role of DHCR24 in WBC
metabolism and inflammation is not known.
One of the advantages of our study is the use of whole blood
rather than isolated peripheral mononuclear cells to avoid gene
expression changes due to variable handling times during
processing [35], in addition to capturing changes in more cell
types. Adipose tissue would be an attractive tissue to analyze in
regard to changes in gene expression following bariatric surgery,
since a higher proportion of adipose transcripts than whole blood
transcripts were found to be correlated with BMI in a population
study [36]. However, blood is simpler to obtain, particularly for
serial sampling; and, genetic cis effects on gene expression are
mostly conserved between adipose tissue and whole blood [36].
Furthermore, white blood cell expression profiling has been shown
to be useful for screening of diseases of non-blood tissues, such as
colorectal cancer [37]. In prior studies, whole blood transcriptome
profiling was used to compare obese and lean subjects, yielding
sets of transcripts that were differentially expressed [13,38]. One
potential complication of the use of whole blood for transcriptome
analysis is that the abundant globin mRNA can interfere with
subsequent analyses. There are several ways to counter this issue,
and we chose NuGen Ovation RNA amplification kit to eliminate
this problem, as it has been shown to be the most efficient method
and yields increased sensitivity [39].
The present study had several limitations. The small sample size
led to a high FDR and prevented the analysis of differential
transcriptome responses to the RYGB and SG surgeries. The
paired t-test analysis with each subjects’ pre and post surgery
whole blood RNA placed on the same Illumina BeadChip
controlled for chip to chip variation; but, this design also
precluded the use of multiple logistic regression to correct for
covariates such as gender and surgery type. Overall, we did not
observe large fold effects on transcript levels, but variations of 10%
to 60% can have meaningful physiological consequences,
particularly in our experimental design that determines changes
in whole blood gene expression levels before and after bariatric
Figure 2. Venn diagram representing the number of transcripts
whose change in expression after bariatric surgery were highly
correlated with percent changes in weight loss, fasting plasma
glucose, and HbA1C content. Seven transcripts were highly
correlated with changes in all three of these clinical characteristics.
doi:10.1371/journal.pone.0016729.g002
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genetic and environmental differences among the subjects. The
expression of many genes decreased after bariatric surgery, and we
presented these reductions as % changes derived from fold
changes of post/pre values, which appears to under represent the
fold effect. For example, a 50% reduction in gene expression
actually represents a 22-fold change. We directly compared the %
changes of two transcripts found significantly altered by weight loss
in both our study and our analysis of the data from Ghosh et al.,
(GEO Accession # GSE18897). We observed that expression of
CEACAM8 decreased by 45% (21.8-fold effect) after bariatric
surgery in our study and by 19% (21.23-fold effect) after diet
induced weight loss in the data of Ghosh et al. We observed that
the expression of MYLIP (myosin regulatory light chain interacting
protein) increased by 29% (1.29-fold) in our study and by 75%
(1.75-fold) in the Ghosh study. Overall, the range of gene
expression changes that were decreased after weight loss was
fairly comparable in the present study (4 to 46% decreased) to our
analysis of the Ghosh data (7 to 63% decreased).
Several of the genes we described whose expression in whole
blood changed after bariatric surgery have been previously found
to be associated with obesity and/or type 2 diabetes. Thus, one
might be able to compare how different diets, drug therapies, and
surgical interventions alter whole blood gene expression profiles,
and determine the correlations of gene expression changes with
clinical improvements in order to examine which pathways are
affected by these different therapeutic regimens. In addition
baseline whole blood transcriptomes can be examined among
subjects who respond differently to different therapeutic treat-
ments for obesity and type 2 diabetes. In the future, whole blood
gene expression profiling might be used for personalized medicine
in order to make informed clinical decisions among the different
therapeutic options.
In conclusion, our pilot study identified many genes whose
expression was markedly altered in whole blood following bariatric
surgery, some of which are related to inflammation and lipid
metabolism. We identified seven genes whose expression changes
were correlated with changes in HbA1C content, weight, and FPG.
Thus, whole blood expression levels of these and potentially other
transcripts identified in this study may be useful as biomarkers
indicative of type 2 diabetes susceptibility, as well as response to
various therapeutic regimens. In addition, this type of study may
illuminate new targets and pathways for intervention.
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